Standard Treatment Or topical doxepin against Pruritus in burn patients - STOP trial

Vereniging Samenwerkende Brandwondencentra Nederland0 个研究点目标入组 108 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Patients with healed burns and itch. Patients are divided into four groups i.e.
•1) patients with partial thickness wounds, not exceeding 4 months postburn
•2) patients with full thickness wounds, not exceeding 4 months postburn
•3) patients with partial thickness wounds between 4 months postburn and 3 years postburn
•4) patients with full thickness wounds between 4 months postburn and 3 years postburn
•Itch intensity as assessed by VAS score greater than or equal to 3
•Patients treated in one of the three Dutch burn centres
•Patients aged 18 years or older

•- Inability to give informed consent by patient or legal representatives
•- Inability to understand and fill in VAS scores and quality of life/pruritus assessment questionnaires, as judged by the treating physician
•- (Active) cutaneous or systemic disease causing itch
•- Any disease or condition which is associated with adverse effects using doxepin, that is:
•Contra-indications Tavegil
•- hypersensitivity to clemastine or other arylalkylamine antihistamines, or any of the excipients
•- porphyria
•Precautions Tavegil:
•- fructose intolerance
•- narrow-angle glaucoma
•- stenosing peptic ulcer
•- pyloroduodenal obstruction
•- prostatic hypertrophy with urinary retention and bladder neck obstruction
•- galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption
•- pregnancy and lactation
•Contra-indications Xepin:
•- hypersensitivity to any of its components.
•Precautions Xepin
•- glaucoma
•- a tendency to urinary retention
•- severe liver disease
•- severe heart disease (including cardiac arrythmias)
•- pregnancy and lactation

发起方

Vereniging Samenwerkende Brandwondencentra Nederland